In view of the rising use of GLP-1 (glucagon-like peptide-1) agonist therapies in India for weight management, obesity, and glycaemic control, Metropolis Healthcare has launched a structured diagnostic framework: three new test packages under its TruHealth brand tailored to different stages of therapy. 

The TruHealth GLP-1 Ready package is intended for individuals before starting GLP-1 therapy  to map baseline metabolic status, including glucose–insulin ratio, lipid levels, liver and kidney health, cardiac risk, nutritional markers, vital signs and ECG. This helps assess readiness and identify pre-existing risks. 

For those already on therapy, TruHealth GLP-1 Monitor offers ongoing biochemical monitoring — tracking evolving metabolic markers, early signals of deficiencies or organ stress, and facilitating timely therapy adjustments. The 3-Pack Subscription option helps maintain regular periodic assessments to build a longitudinal picture of metabolic changes and therapy response. 

Metropolis’ leadership explains that with growing numbers of people turning to GLP-1 medications  for obesity or diabetes  a robust diagnostic support system becomes critical; many may otherwise begin or continue treatment without a clear picture of their metabolic health or how their body responds. These packages aim to fill that gap and promote safer, personalised metabolic care.